Comparative Pharmacology
Head-to-head clinical analysis: ACTIFED W CODEINE versus METHADOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTIFED W CODEINE versus METHADOSE.
ACTIFED W/ CODEINE vs METHADOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Codeine is a prodrug that is metabolized to morphine, which acts as a mu-opioid receptor agonist; triprolidine is an H1 receptor antagonist. The combination produces antitussive and antihistamine effects.
Methadone is a mu-opioid receptor agonist; it also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake, contributing to its analgesic and detoxification effects. It has a long half-life and reduces opioid craving and withdrawal symptoms.
Adults: 10 mL orally every 4-6 hours as needed, not to exceed 4 doses in 24 hours. Each 10 mL contains 10 mg codeine, 4 mg triprolidine, 60 mg pseudoephedrine.
Oral: 20-40 mg once daily, titrated to effect; for opioid dependence, typical maintenance 80-120 mg/day. IV: 2.5-10 mg every 8-12 hours.
None Documented
None Documented
Codeine: 2.5-4 hours; pseudoephedrine: 5-8 hours; triprolidine: 3-6 hours. Context: Codeine half-life prolonged in hepatic impairment and CYP2D6 poor metabolizers; pseudoephedrine half-life increased with alkaline urine.
Terminal elimination half-life range: 8–59 hours (mean ~20–35 hours). In chronic use, half-life may increase due to accumulation. Context: The long half-life supports once-daily dosing for opioid dependence but requires careful titration to avoid accumulation.
Renal: 60-80% (codeine and metabolites, primarily as codeine-6-glucuronide, norcodeine, and morphine); unchanged codeine <10%. Fecal: <10%. Biliary: minor.
Primarily renal (approximately 80%) as inactive metabolites, with about 20% eliminated via feces. Less than 10% excreted unchanged.
Category D/X
Category C
Opioid Agonist
Opioid Agonist